In summary, our study not only provides a novel risk signature for prognosis prediction of breast cancer based on HTRs, but also highlights the activation of HTR2A as a novel therapeutic strategy to improve breast cancer prognosis via mobilizing CD8+T cells. Here, HTR2A is linked to breast cancer.